이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

광범위 소세포폐암 환자의 1차 유도 또는 유지 관리로서 카보플라틴 유무에 관계없이 아테졸리주맙과 I-DXd를 병용하는 연구(IDeate-Lung03)

2026년 9월 28일 업데이트: Daiichi Sankyo

1차 유도 또는 유지요법으로 카보플라틴 유무에 관계없이 아테졸리주맙과 병용하여 B7-H3 항체-약물 접합체(ADC)인 이피나타맙 데룩스테칸(I-DXd)에 대한 1b/2상 다기관 공개 라벨 연구입니다. 광범위 소세포폐암(ES-SCLC) 환자(IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

This study consists of two parts and two cohorts: Part A (Phase 1b; Safety Run-in) and Part B (Phase 2; Dose Optimization), Cohort 1 (I-DXd in maintenance) and Cohort 2 (I-DXd in induction + maintenance).

The primary objective of this study is to evaluate the safety and tolerability of I-DXd in combination with atezolizumab with or without carboplatin by assessing treatment-emergent adverse events (TEAEs) and other safety parameters which will inform optimal dose selection of I-DXd in the combination regimens (Dose Optimization Part B) of this study.

연구 유형

중재적

등록 (추정된)

123

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • 모병
        • University of Alabama -Birmingham
        • 연락하다:
          • Principal Investigator
    • Arizona
      • Phoenix, Arizona, 미국, 85054
        • 모병
        • Mayo Clinic Arizona
        • 연락하다:
          • Principal Investigator
    • California
      • Los Angeles, California, 미국, 90095
        • 아직 모집하지 않음
        • David Geffen School of Medicine
        • 연락하다:
          • Principal Investigator
      • Newport Beach, California, 미국, 92663
        • 모병
        • Hoag Memorial Hospital Presbyterian
        • 연락하다:
          • Principal Investigator
    • Florida
      • Jacksonville, Florida, 미국, 32224
        • 모병
        • Mayo Clinic-Jacksonville
        • 연락하다:
          • Principal Investigator
      • Orlando, Florida, 미국, 32804
        • 모병
        • Advent Health Orlando
        • 연락하다:
          • Principal Investigator
      • Tampa, Florida, 미국, 33612
        • 모병
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • 모병
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
        • 연락하다:
          • Principal Investigator
    • Michigan
      • Detroit, Michigan, 미국, 48202
        • 모집하지 않고 적극적으로
        • Henry Ford Hospital
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55455
        • 모병
        • Regents of the University of Minnesota
        • 연락하다:
          • Principal Investigator
      • Rochester, Minnesota, 미국, 55905
        • 모병
        • Mayo Clinic
        • 연락하다:
          • Principal Investigator
    • New Hampshire
      • Lebanon, New Hampshire, 미국, 03766
        • 모병
        • Dartmouth-Hitchcock Medical Center
        • 연락하다:
          • Principal Investigator
    • New Jersey
      • East Brunswick, New Jersey, 미국, 08816
        • 모병
        • Astera Cancer Care
      • Hackensack, New Jersey, 미국, 07601
        • 모병
        • John Theurer Cancer Center At Hackensack Umc
        • 연락하다:
          • Principal Investigator
    • New York
      • Mineola, New York, 미국, 11501
        • 모병
        • NYU Langone Hospital - Long Island
        • 연락하다:
          • Principal Investigator
      • Mineola, New York, 미국, 11501
        • 모병
        • New York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu Langone
        • 연락하다:
          • Principal Investigator
      • New York, New York, 미국, 10021
        • 모병
        • Memorial Sloan Kettering Cancer Center
        • 연락하다:
          • Principal Investigator
      • New York, New York, 미국, 10461
        • 모병
        • Montefiore Medical Center
      • New York, New York, 미국, 10032
        • 모병
        • Columbia University Hervert Irving Comprehensive Cancer Center
        • 연락하다:
          • Principal Investigator
    • Pennsylvania
      • Lancaster, Pennsylvania, 미국, 17601
        • 모병
        • Lancaster General Hospital - Ann B Barshinger Cancer Institute
      • Philadelphia, Pennsylvania, 미국, 19104
        • 모병
        • University of Pennsylvania, Abramson Cancer Center
      • Philadelphia, Pennsylvania, 미국, 19107
        • 모병
        • Thomas Jefferson University Hospital - Central
        • 연락하다:
          • Principal Investigator
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • Scri Oncology Partners
        • 연락하다:
          • Principal Investigator
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • 모병
        • Next Virginia
        • 연락하다:
          • Principal Investigator
    • Washington
      • Vancouver, Washington, 미국, 98684
        • 모병
        • Northwest Cancer Specialists, P.C.-Vancouver
        • 연락하다:
          • Principal Investigator
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • 모병
        • Medical College of Wisconsin
        • 연락하다:
          • Principal Investigator
      • Barcelona, 스페인, 08036
        • 모병
        • Hospital Clinic de Barcelona
        • 연락하다:
          • Principal Investigator
      • Barcelona, 스페인, 8035
        • 모병
        • Hospital Universitari Vall D'Hebron
        • 연락하다:
          • Principal Investigator
      • Girona, 스페인, 17007
        • 모병
        • Ico Girona - Hospital Universitari de Girona Dr Josep Trueta
        • 연락하다:
          • Principal Investigator
      • L'Hospitalet de Llobregat, 스페인, 08908
        • 모병
        • ICO l'Hospitalet - Hospital Duran i Reynals
        • 연락하다:
          • Principal Investigator
      • Madrid, 스페인, 28041
        • 모병
        • Hospital Universitario 12 de Octubre
        • 연락하다:
          • Principal Investigator
      • Madrid, 스페인, 28007
        • 모병
        • Hospital General Universitario Gregorio Marañon
        • 연락하다:
          • Principal Investigator
      • Madrid, 스페인, 28034
        • 모병
        • Hospital Universitario Ramon Y Cajal
        • 연락하다:
          • Principal Investigator
      • Madrid, 스페인, 28223
        • 모병
        • Next Madrid
        • 연락하다:
          • Principal Investigator
      • Málaga, 스페인, 29010
        • 모병
        • Hospital Regional Universitario de Malaga
        • 연락하다:
          • Principal Investigator
      • Seville, 스페인, 41009
        • 모병
        • Hospital Universitario Virgen Macarena
        • 연락하다:
          • Principal Investigator
      • Seville, 스페인, 41013
        • 모병
        • Hospital Universitario Virgen Del Rocio
        • 연락하다:
          • Principal Investigator
      • Vigo, 스페인, 36312
        • 모병
        • Hospital Alvaro Cunqueiro
        • 연락하다:
          • Principal Investigator
      • Himeji-shi, 일본, 670-8520
        • 모병
        • NHO Himeji Medical Center
      • Hirakata-shi, 일본, 573-1191
        • 모병
        • Kansai Medical University Hospital
        • 연락하다:
          • Principal Investigator
      • Kashiwa, 일본, 277-8577
        • 모병
        • National Cancer Center Hospital East
        • 연락하다:
          • Principal Investigator
      • Kumamoto, 일본, 861-4193
        • 모병
        • Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital
        • 연락하다:
          • Principal Investigator
      • Kōtoku, 일본, 135-8550
        • 모병
        • The Cancer Institute Hospital of Jfcr
        • 연락하다:
          • Principal Investigator
      • Nagaizumi-cho, 일본, 411-8777
        • 모병
        • Shizuoka Cancer Center
        • 연락하다:
          • Principal Investigator
      • Niigata, 일본, 951-8566
        • 모병
        • Niigata Cancer Center Hospital
        • 연락하다:
          • Principal Investigator
      • Okayama, 일본, 700-8558
        • 모병
        • Okayama University Hospital
        • 연락하다:
          • Principal Investigator
      • Tokushima, 일본, 770-8503
        • 모병
        • Tokushima University Hospital
      • Toyoake-shi, 일본, 470-1192
        • 모병
        • Fujita Health University Hospital
      • Ōsaka-sayama, 일본, 589-8511
        • 모병
        • Kindai University Hospital
        • 연락하다:
          • Principal Investigator
      • Lille, 프랑스, 59037
        • 모병
        • Hopital Albert Calmette - Chu Lille
        • 연락하다:
          • Principal Investigator
      • Lyon, 프랑스, 69008
        • 모병
        • Centre Léon Bérard
        • 연락하다:
          • Principal Investigator
      • Marseille, 프랑스, 13005
        • 모병
        • Hôpital de la Timone
        • 연락하다:
          • Principal Investigator
      • Paris, 프랑스, 75005
        • 모병
        • Institut Curie - Site de Paris
        • 연락하다:
          • Principal Investigator
      • Paris, 프랑스, 75020
        • 모병
        • Hopital Tenon
        • 연락하다:
          • Principal Investigator
      • Rennes, 프랑스, 35000
        • 모병
        • Chu Rennes - Hopital Pontchaillou
        • 연락하다:
          • Principal Investigator
      • Saint-Herblain, 프랑스, 44805
        • 모병
        • CHU Nantes - Hôpital Guillaume et René Laënnec
        • 연락하다:
          • Principal Investigator
      • Suresnes, 프랑스, 92151
        • 모병
        • Hôpital Foch
        • 연락하다:
          • Principal Investigator
      • Villejuif, 프랑스, 94805
        • 아직 모집하지 않음
        • Institut Gustave Roussy
        • 연락하다:
          • Principal Investigator

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

A full list of inclusion/exclusion criteria are available in the protocol.

Inclusion Criteria

Participants must meet all of the following criteria to be eligible for enrollment into the study:

  1. Sign and date the informed consent form (ICF), prior to the start of any study-specific qualification procedures.

  2. Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.

  3. Has histologically or cytologically confirmed diagnosis of ES-SCLC who will require first-line (IL) therapy.

  4. For Cohort 1, participant has received 4 cycles of 1L induction therapy with carboplatin, etoposide, and atezolizumab for ES-SCLC with ongoing CR PR, CR, or SD per RECIST v1.1 assessed by the investigator.

    For Cohort 2, participant has received no prior treatment for ES-SCLC.

  5. For Cohort 2, participant has at least one measurable lesion according to RECIST v1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by the investigator.

  6. For Cohort 2, participant must have at least one lesion, amenable to core biopsy, and must consent to provide a pretreatment biopsy tissue sample and on-treatment biopsy.

  7. Has ECOG PS of ≤1 (assessed within 7 days before enrollment/randomization).

  8. Has adequate organ and bone marrow function within 7 days before the start of study treatment as specified in the study protocol.

  9. A female subject of childbearing potential (POCBP) is eligible to participate if the following conditions are met:

    1. Subject is not pregnant as confirmed by highly sensitive pregnancy test during Screening (within 3 days prior to enrollment/randomization)
    2. Subject does not breastfeed during the treatment period and for at least 8/5/6 months after last dose of I-DXd/atezolizumab/carboplatin, respectively.
    3. Subject agrees to adhere to a contraceptive method that is highly effective and agrees not to donate eggs (ova, oocytes) to others or freeze/store eggs during the treatment period and for at least the time needed to eliminate each study drug after the last dose. The length of time required to continue contraception and avoid donating/freezing eggs after last dose for I-DXd/atezolizumab/carboplatin is 8/5/6 months, respectively. Preservation of eggs may be considered prior to first dose of study drug.
  10. A male subject capable of producing sperm is eligible to participate if he agrees to the following during the intervention period and for at least the time needed to eliminate each study drug. The length of time required to continue contraception and avoid donating sperm after last dose for I-DXd/atezolizumab/carboplatin is 6/5/6 months, respectively.

    1. Avoid donating sperm.
    2. Adhere to either of the contraception methods: true abstinence from penile-vaginal intercourse or uses a penile/external condom when having penile-vaginal intercourse with a non-subject of childbearing potential plus partner use of an additional contraceptive method.
  11. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
  2. Prior discontinuation of an ADC that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
  3. Has received prior treatment with CD137 agonists or ICIs, including anti-cytotoxic T-cell lymphocyte-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, except for atezolizumab for Cohort 1.
  4. Has inadequate washout period before enrollment/randomization as specified in the study protocol.
  5. Has any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event.
  6. Has clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.
  7. Has clinically significant corneal disease.
  8. Has uncontrolled or significant cardiovascular disease,.
  9. Has history of (non-infectious) ILD/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
  10. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  11. Is on chronic steroid treatment (dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease, topical steroids (for mild skin conditions), or intra-articular steroid injections.
  12. Has history of malignancy other than SCLC within the 5 years prior to randomization/enrollment, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial gastrointestinal tract tumors, and non-muscle invasive bladder cancer curatively resected by endoscopic surgery.
  13. Has history of allogeneic bone marrow, stem cell, or solid organ transplant.
  14. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE V5.0, Grade ≤1 or baseline.
  15. Has history of hypersensitivity to the drug substances, inactive ingredients in the drug product or severe hypersensitivity reactions to other monoclonal antibodies.
  16. Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.
  17. Has active or uncontrolled human immunodeficiency virus (HIV) infection.
  18. Has active or uncontrolled hepatitis B or C virus (HBV or HCV) infection.
  19. Has history of autoimmune disease.
  20. Has any evidence of severe or uncontrolled systemic diseases.
  21. Has received a live vaccine within 30 days prior to the first dose of study drug.
  22. Is a female who is pregnant or breastfeeding or planning to become pregnant.
  23. Has prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.
  24. Has psychological, social, familial, or logistical factors that would prevent regular follow-up

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort 1, Part A: Maintenance Only (I-DXd 12 mg/kg)

Part A (Safety Run-in): Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

A 5-day surveillance period between each of the first 3 participants (up to a maximum of 9 participants) dosed is included as a safety measure.

Intravenous administration

다른 이름들:
  • I-DXd

Intravenous administration

실험적: Cohort 2, Part A: Induction + Maintenance (I-DXd 8 mg/kg)

Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

다른 이름들:
  • I-DXd

Intravenous administration

Intravenous administration

실험적: Cohort 2, Part A: Induction + Maintenance (I-DXd 12 mg/kg)

Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

다른 이름들:
  • I-DXd

Intravenous administration

Intravenous administration

실험적: Cohort 1, Part B: Maintenance (I-DXd 8 mg/kg)

Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W

Intravenous administration

다른 이름들:
  • I-DXd

Intravenous administration

실험적: Cohort 1, Part B: Maintenance (I-DXd 12 mg/kg)

Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

다른 이름들:
  • I-DXd

Intravenous administration

실험적: Cohort 2, Part B: Induction + Maintenance (I-DXd 8 mg/kg)

Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

다른 이름들:
  • I-DXd

Intravenous administration

Intravenous administration

실험적: Cohort 2, Part B: Induction + Maintenance (I-DXd 12 mg/kg)

Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of IL I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×minIV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

다른 이름들:
  • I-DXd

Intravenous administration

Intravenous administration

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
카보플라틴 유무에 관계없이 아테졸리주맙과 병용한 I-DXd에 따른 용량 제한 독성을 보고한 참가자 수(파트 A)
기간: 주기 1 1일차부터 1주기 21일차(각 주기는 21일)
주기 1 1일차부터 1주기 21일차(각 주기는 21일)
카보플라틴 유무에 관계없이 아테졸리주맙과 병용한 I-DXd 이후 치료로 인해 발생한 이상반응이 발생한 전체 참가자 수(파트 A 및 B)
기간: 기준 최대 37개월
기준 최대 37개월

2차 결과 측정

결과 측정
측정값 설명
기간
Progression-free Survival As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)
기간: From start date of study drug to the earlier date of the first objective documentation of radiographic disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause, whichever occurs first, up to approximately 37 months

Progression-free survival is defined as the time from the enrollment/randomization date to the earlier of the dates of the first documentation of disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause.

From start date of study drug to the earlier date of the first objective documentation of radiographic disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause, whichever occurs first, up to approximately 37 months
Objective Response Rate Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
기간: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Objective response rate (ORR) is defined as proportion of subjects who achieved a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BICR and investigator according to RECIST v1.1.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Duration of Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
기간: From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 37 months

Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (confirmed complete response [CR] or confirmed partial response [PR]) to the date of the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. The DoR will be calculated for responding participants (confirmed PR or confirmed CR) only.

From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 37 months
Disease Control Rate As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
기간: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD by BICR and investigator assessment per RECIST v1.1.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Clinical Benefit Rate as Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
기간: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Clinical benefit rate (CBR) is defined as the proportion of participants who achieved a best overall response of confirmed CR, confirmed PR, or SD lasting for at least 180 days.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Time to Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
기간: From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 37 months

Time to response (TTR) is defined as the time from the date of enrollment/randomization to the date of the first documentation of objective response (confirmed CR or confirmed PR) in responding subjects.

From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 37 months
Best Percentage Change in the Sum of Diameters (SoD) of Measurable Tumors As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
기간: Baseline up to approximately 37 months

The best percentage change in SoD is defined as the percentage change in the smallest SoD from all post-baseline tumor assessments, taking as reference the baseline SoD.

Baseline up to approximately 37 months
Overall Survival Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)
기간: From the start date of study drug to the date of death due to any cause, whichever occurs first, up to approximately 37 months

Time from the date of enrollment/randomization to the date of death due to any cause.

From the start date of study drug to the date of death due to any cause, whichever occurs first, up to approximately 37 months
Pharmacokinetic Parameter Maximum Serum Concentration of I-DXd
기간: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Maximum serum concentration (Cmax) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
Pharmacokinetic Parameter Time to Maximum Serum Concentration of I-DXd
기간: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Time to maximum serum concentration (Tmax) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
Pharmacokinetic Parameter Area Under the Concentration Curve of I-DXd
기간: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Area under the concentration-time curve up to the last quantifiable time (AUClast) and Area under the concentration-time curve during dosing interval (AUCtau) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
The Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive At Any Time and Who Have A Treatment-emergent Anti-Drug Antibody
기간: Baseline up to approximately 37 months

The ADA prevalence, which is the percentage of participants who are ADA positive at any time point (baseline or postbaseline), as well as the ADA incidence, which is the proportion of participants having treatment-emergent ADA during the study period, will be reported.

Baseline up to approximately 37 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 책임자: Global Clinical Leader, Daiichi Sankyo

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 7월 22일

기본 완료 (추정된)

2027년 7월 20일

연구 완료 (추정된)

2028년 2월 20일

연구 등록 날짜

최초 제출

2024년 1월 2일

QC 기준을 충족하는 최초 제출

2024년 4월 8일

처음 게시됨 (실제)

2024년 4월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 28일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • DS7300-189
  • 2023-509629-36 (기타 식별자: EU CT)
  • 2031240089 (기타 식별자: JRCT)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

IPD 공유 기간

Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

IPD 공유 액세스 기준

Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .